CA2203236A1 - Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations - Google Patents

Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations

Info

Publication number
CA2203236A1
CA2203236A1 CA 2203236 CA2203236A CA2203236A1 CA 2203236 A1 CA2203236 A1 CA 2203236A1 CA 2203236 CA2203236 CA 2203236 CA 2203236 A CA2203236 A CA 2203236A CA 2203236 A1 CA2203236 A1 CA 2203236A1
Authority
CA
Canada
Prior art keywords
antibody
molecule
region
chain
encodes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2203236
Other languages
English (en)
Inventor
Ira Pastan
Itai Benhar
Eduardo A. Padlan
Sun-Hee Jung
Byungkook Lee
David Fitzgerald
Ulrich Brinkmann
Lee Pai
Mark Willingham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/331,398 external-priority patent/US5608039A/en
Priority claimed from US08/331,397 external-priority patent/US5981726A/en
Priority claimed from US08/331,396 external-priority patent/US5889157A/en
Application filed by Individual filed Critical Individual
Publication of CA2203236A1 publication Critical patent/CA2203236A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/34—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood group antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention porte sur des anticorps à chaîne unique recombinants capables de se lier spécifiquement à un antigène glucidique de type Lewis Y et sur des protéines de fusion comprenant ces anticorps. Plus particulièrement, l'invention a trait à des régions Fv (ScFv) à chaîne unique des anticorps monoclonaux B1, B3 et B5, à des régions Fv à chaîne unique humanisées de ces anticorps et à des protéines de fusion comprenant ces régions scFv. L'invention a trait également à un certain nombre de mutations stabilisatrices de l'anticorps B3 monoclonal liant un antigène Lewis B. En outre, l'invention a trait à des méthodes de détection des cellules renfermant un antigène de type Lewis Y chez un patient et à des méthodes permettant de tuer ces cellules ou d'inhiber leur croissance. L'invention porte également sur une méthode d'amélioration de l'affinité des anticorps dépourvus d'une sérine en position 95 de la région VH, qui consiste à placer une sérine en position 95 par mutation.
CA 2203236 1994-10-28 1995-10-26 Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations Abandoned CA2203236A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US08/331,398 1994-10-28
US08/331,398 US5608039A (en) 1990-10-12 1994-10-28 Single chain B3 antibody fusion proteins and their uses
US08/331,397 US5981726A (en) 1990-10-12 1994-10-28 Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
US08/331,396 1994-10-28
US08/331,396 US5889157A (en) 1990-10-12 1994-10-28 Humanized B3 antibody fragments, fusion proteins, and uses thereof
US08/331,397 1994-10-28

Publications (1)

Publication Number Publication Date
CA2203236A1 true CA2203236A1 (fr) 1996-05-09

Family

ID=27406791

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2203236 Abandoned CA2203236A1 (fr) 1994-10-28 1995-10-26 Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations

Country Status (4)

Country Link
EP (1) EP0796334A1 (fr)
AU (1) AU717611B2 (fr)
CA (1) CA2203236A1 (fr)
WO (1) WO1996013594A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU766149B2 (en) * 1998-10-31 2003-10-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Variants of humanized anti-carcinoma monoclonal antibody CC49
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
EP1434800B1 (fr) * 2001-09-14 2010-12-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Immunoglobuline dotee d'un squelette particulier ; methodes de fabrication et d'utilisation
CA2420494A1 (fr) * 2003-02-28 2004-08-28 Universite De Sherbrooke Fonction de l'antigene tumoral ca 125 et utilisations therapeutiques de celui-ci
EP1532162B1 (fr) 2002-06-28 2013-08-07 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Les cc49, anti-tag-72 humanises servant au diagnostic et au traitement de tumeurs chez l'homme
CU23403A1 (es) 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
MY146381A (en) * 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
GB201910899D0 (en) * 2019-07-31 2019-09-11 Scancell Ltd Binding members

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2120153C (fr) * 1991-09-30 2006-06-06 Ira Pastan Immunotoxines recombinantes

Also Published As

Publication number Publication date
EP0796334A1 (fr) 1997-09-24
AU717611B2 (en) 2000-03-30
AU4135596A (en) 1996-05-23
WO1996013594A8 (fr) 2000-04-06
WO1996013594A1 (fr) 1996-05-09

Similar Documents

Publication Publication Date Title
US5990296A (en) Single chain B3 antibody fusion proteins and their uses
US6287562B1 (en) Methods of inhibiting the growth of cells bearing LewisY antigens using B1, B3, or B5 targeted immunoconjugates
JP6110321B2 (ja) 細胞表面の前立腺特異的膜抗原に対するモノクローナル抗体および単鎖抗体フラグメント
JP3835827B2 (ja) 悪性細胞に対する、ｏｎｃタンパク質を含む、免疫毒素
AU770718B2 (en) Use of genetically engineered antibodies to CD38 to treat multiple myeloma
JP6326137B2 (ja) 抗ｈｅｒ２抗体及びその結合体
EP0699756B1 (fr) Anticorps BR96 mutantsréagissant aux carcinomes humains
JP2004500828A (ja) Ｍｕｃｉｎ−１特異的結合メンバー及びその使用方法
AU2001249760A1 (en) Mucin-1 specific binding members and methods of use thereof
CN111201240B (zh) 特异性地结合muc1的抗体及其用途
IL135775A (en) Antibodies and immunoconjugates having high binding affinity for mesothelin
JP2002502363A (ja) 改変／キメラスーパー抗原およびその使用
US5981726A (en) Chimeric and mutationally stabilized tumor-specific B1, B3 and B5 antibody fragments; immunotoxic fusion proteins; and uses thereof
WO1995027732A2 (fr) Ligands et molecules chimeriques a permutation circulaire
CA2203236A1 (fr) Fragments d'anticorps a specificite tumorale, proteines de fusion, et leurs utilisations
US5728821A (en) Mutant BR96 antibodies reactive with human carcinomas
JP3236667B2 (ja) ヒト型モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ並びに抗腫瘍剤
EP1085908B1 (fr) Immunotoxine de recombinaison dirigee vers la glycoproteine de l'enveloppe gp120 du vih
KR20020049054A (ko) 항체
WO2004020574A2 (fr) Fragment scfv en rapport avec la cathepsine l humaine et leurs procedes d'utilisation
WO2002058624A9 (fr) Generation in situ specifique d'un site de l'allicine au moyen d'un systeme de distribution cible d'alliinase pour le traitement des cancers, tumeurs, maladies infectieuses et autres maladies sensibles a l'allicine
CN115521375A (zh) 抗新冠病毒广谱中和性单抗的制备和应用
JPH10508202A (ja) 腫瘍特異性抗体断片、融合タンパク質、およびそれらの使用

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead